Eli Lilly's performance in the biopharmaceutical sector reflects its strong market position, despite facing challenges. The ...
Viking Therapeutics (NASDAQ: VKTX) soared into the spotlight about a year ago when it delivered promising data on a drug ...
We recently compiled a list of the Jim Cramer Discusses These 12 Stocks, Elon Musk & President Trump. In this article, we are ...
The deal with Lilly is a crucial boost for Organovo, which ended last year with just $1.2 million in cash and nearly $350 million in debt. Organovo FXR is a clinical drug program focused on farnesoid ...
The prevalence of type 2 diabetes is rising globally, with a disproportionate impact on individuals in low-income and middle-income countries, where access to care and new therapies is often limited.
Patrik Jonsson is the president of Eli Lilly & Co.'s cardiometabolic health unit. "Eli Lilly to Offer Higher Doses of Obesity Drug Zepbound at Discounted Prices," at 9:48 a.m. ET, incorrectly said his ...
Eli Lilly said it has launched new doses of its obesity treatment drug and reduced its prices.
Legislators may launch a study of how weight loss drugs might reduce costs in the Iowa Medicaid program. Jeffrey Boeyink is a ...
Nimbus Therapeutics, LLC, a biotechnology company that designs and develops medicines leveraging its computational drug discovery engine, has achieved a significant preclinical milestone under its ...
Pharmaceutical giant Eli Lilly is once again expanding the supply of its weight-loss drug Zepbound and cutting the cost for ...
The data highlight the possibility of SGLT 1/2 inhibitors having protective effects beyond heart failure and diabetes.
Hugely popular weight loss drugs known as GLP-1's are finally getting cheaper, well at least one is, and that's the case with ...